Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacogenomics to Benefit from Steven Burrill s New $300M-$500M Life Sciences Venture Capital Fund

NEW YORK, Jan. 7 (GenomeWeb News) - Burrill & Company, a San Francisco-based life sciences merchant bank, is launching a $300-million to $500-million venture capital fund dedicated to biotechnology, personalized medicine, new diagnostics, and devices.

 

"We're looking at tools and technologies that will move us further and faster towards personalized and predictive medicine," Steven Burrill, CEO of the company, told GenomeWeb News today. "Biomarkers would be a real important part of that, as well as technology that will allow you to walk into a lab and get your genome sequenced."

 

According to Burrill, the new fund, called the Burrill Life Sciences Capital Fund III, will go to 20 to 25 companies worldwide at various stages of development, from seed and early stage to mezzanine levels. Each company will receive about $20 million in funding.

 

Burrill & Company currently has $500 million under management. BLSCF III is Burrill's third generation of venture funds. First generation funds, established in 1998, include a human health-care focused fund called the Burrill Biotechnology Capital Fund, the Burrill Agbio Capital Fund and the Burrill Nutraceuticals Capital Fund. Second generation funds, established in 2002, include the $211 million Burrill Life Sciences Capital fund.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.